Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aquestive Therapeutics reports robust 2022 performance and strategic growth plans

Aquestive Therapeutics showcased strong performance in 2022, focusing on innovation, strategic partnerships, and financial management.
While facing challenges such as generic competition and financial discipline, the company is well-positioned to capitalize on opportunities for growth and market expansion.
With a clear emphasis on advancing key products, securing collaborations, and navigating market dynamics, Aquestive is poised for continued success in 2023 and beyond.

Aquestive Therapeutics reports strong Q1 performance and eyes global expansion

Aquestive Therapeutics' Q1 performance reflects strong revenue growth, debt reduction, and strategic advancements in product development.
While facing challenges in European pricing and Chinese market visibility, the company maintains a focus on operational efficiency and market expansion.
Opportunities in FDA interactions, market access, and upcoming regulatory meetings position Aquestive for future growth and product success.
Overall, Aquestive Therapeutics demonstrates resilience and strategic planning in navigating market challenges and driving growth.

Aquestive Therapeutics reports improved Q2 performance and eyes global expansion

Aquestive Therapeutics reported a strong Q2 2023 performance with revenue growth and reduced net loss. The company faces financial challenges but holds strengths in its financial position and growth outlook. Opportunities for expansion and partnerships present avenues for future growth.

Aquestive Therapeutics reports strong Q3 performance and optimistic growth outlook

Aquestive Therapeutics showcased robust financial performance, strategic debt refinancing, and promising product developments in Q3 2023. While facing challenges in competitive intelligence and trial efficiency, the company is optimistic about future growth opportunities and remains focused on expanding its capabilities.

Aquestive reports robust Q4 earnings, eyes billion-dollar sales opportunities

Aquestive Therapeutics showcases strong financial performance in Q4 2023, with revenue growth and improved EBITDA loss, setting a positive trajectory for future growth. Strategic focus on launching Anaphylm and Libervant, along with proactive commercial preparations, underlines the company's commitment to innovation and market expansion. Despite regulatory and competitive challenges, Aquestive's confidence in FDA processes and international market exploration present promising opportunities for long-term success.

Aquestive Therapeutics reports revenue growth and plans for future launches

Aquestive Therapeutics reported revenue growth in Q3 2024 driven by successful product launches and positive study results, despite increased expenses.
The company's focus on key programs and upcoming milestones signals a commitment to innovation and addressing market needs for sustained growth.
While facing challenges in managing expenses and profitability, Aquestive's strong financial position and strategic initiatives offer opportunities for future growth and market expansion.
Overall, Aquestive's performance in Q3 2024 reflects a balance between investment in future growth and financial stability, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aquestive: Continues To Evolve Into A Promising Long-Term Investment

WARREN, N.J., Dec.  12, 2019  (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq:AQST) (“Aquestive”), a specialty pharmaceutical company focused on developing and commercializing differentiated products to meet patients’ unmet needs and solve therapeutic problems, today announced the pricing of its public offering of 7,000,000 shares of common stock at a public offering price of $5.00 per share for aggregate gross proceeds of $35.0 million. All of the shares in the offering are being offered by Aquestive. In addition, Aquestive granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of its common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about on December 17, 2019, subject to the satisfaction of customary closing conditions.

Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock

Aquestive Therapeutics Inc. (NASDAQ: AQST) shares jumped early on Monday after the firm announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its therapeutic candidate Libervant (diazepam) buccal film.

Why This Seizure Treatment Could Be the Next Big Thing

WARREN, N.J., Dec.  02, 2019  (GLOBE NEWSWIRE) --  Aquestive Therapeutics, Inc.  (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced the completion, as planned, of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its therapeutic candidate Libervant™ (diazepam) Buccal Film for the management of seizure clusters.  Libervant has received orphan drug designation from the FDA.

Aquestive Therapeutics Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters

Aquestive Therapeutics, Inc. (NASDAQ: AQST) shares jumped on Monday after the firm announced that its treatment of amyotrophic lateral sclerosis (ALS), Exservan, received early-action approval from the U.S. Food and Drug Administration (FDA).

A Big Step Forward For the Treatment of ALS

Shares of Aquestive Therapeutics Inc.  jumped 20% in premarket trading on the news that the Food and Drug Administration approved Exservan Oral Film as a treatment for amyotrophic lateral sclerosis (ALS), an orphan disease that affects about 30,000 people in the U.S.

Aquestive shares jump on FDA approval

WARREN, N.J., Nov.  13, 2019  (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that it granted a license to Zambon S.p.A. for the development and commercialization of Riluzole Oral Film (ROF) in the European Union for the treatment of amyotrophic lateral sclerosis (ALS).  Zambon is a multinational pharmaceutical company strongly committed to innovating cure and care to make patients’ lives better, with a focus on the central nervous system (CNS) therapeutic area.

Aquestive Therapeutics Licenses Riluzole Oral Film to Zambon for Development and Commercialization in the EU for Patients with ALS

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call Transcript

WARREN, N.J., Oct.  15, 2019  (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced, in response to Indivior PLC’s press release issued earlier today of Indivior’s intent to cease production of its authorized generic buprenorphine-naloxone film product, that the Company is reaffirming its full year 2019 total revenue guidance.  Full year 2019 total revenue is now expected to be at the top end of the Company’s guidance range of $38 million to $45 million. Full year 2019 revenue from the Company’s Suboxone® franchise is expected to be at the top end of its guidance range of $29 million to $32 million.  As of October 2019, Suboxone and the authorized generic buprenorphine-naloxone film continue to retain approximately 75% of the market for film treatments of opioid dependence, of which a substantial majority of its retained market share is branded Suboxone.

Aquestive Therapeutics Reaffirms Full Year 2019 Revenue Guidance and Will Announce Third Quarter 2019 Financial Results and Recent Business Highlights on November 6, 2019

- Represents Significant Proof-of-Concept Milestone for Sublingual Epinephrine Pipeline Product -

Aquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine)

Aquestive Therapeutics is moving closer to passing some key milestones and some noteworthy catalysts. Investors looking to add to start a AQST position need to remain vigilant around these catalysts.

Aquestive Therapeutics: Finally Looking For Entry Ahead Of Key Catalysts

WARREN, N.J., Aug.  26, 2019  (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that the management team is scheduled to present at the H.C. Wainwright 21st Annual Investment Conference and conduct one-on-one meetings at Lake Street’s 3rd Annual Best Ideas Growth (B.I.G.) Conference.

Aquestive Therapeutics to Attend Two Upcoming Investor Conferences

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q2 2019 Results - Earnings Call Transcript

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2019 Results - Earnings Call Transcript

Aquestive Therapeutics has launched its first proprietary CNS product Sympazan for the treatment of seizures in LGS patients.

Aquestive Therapeutics: Transitioning Their Own Proprietary Products

Aquestive Therapeutics might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aquestive Therapeutics Upgraded to Buy: Here's Why

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2018 Results - Earnings Call Transcript

News for Aquestive Therapeutics Inc Stock (AQST)